Cabaletta Bio to participate in Guggenheim Biotech Summit 2026, presenting its cell therapies for autoimmune diseases.
Quiver AI Summary
Cabaletta Bio, Inc., a late-stage clinical biotechnology company aimed at developing curative targeted cell therapies for autoimmune diseases, announced its participation in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026, at 9:30 a.m. ET in New York City. A live webcast will be available on the company's website, along with replays for 30 days. The company is advancing its CARTA platform, particularly focusing on its investigational therapy rese-cel, a human CD19-CAR T cell, which is being evaluated in the RESET clinical development program across various therapeutic areas. Cabaletta Bio is headquartered in Philadelphia, PA.
Potential Positives
- Cabaletta Bio will participate in a prominent industry event, the Guggenheim Emerging Outlook: Biotech Summit 2026, enhancing its visibility and credibility in the biotechnology sector.
- The company is focusing on developing innovative targeted cell therapies for autoimmune diseases, which is a significant and potentially lucrative area within biotechnology.
- The lead CARTA strategy involving rese-cel represents a novel approach, with ongoing evaluation in a clinical program that spans multiple therapeutic areas, highlighting the breadth of its potential impact.
Potential Negatives
- Participation in a biotech summit may indicate the company is relying on external validation and interest, which could signal a lack of confidence in its current progress or pipeline outcomes.
- The emphasis on "curative" therapies may set high expectations that could lead to disappointment if upcoming results do not meet these ambitious claims.
- There is no information provided about any recent clinical trial successes or progress updates, which may raise concerns among investors about the effectiveness of their therapies.
FAQ
What is Cabaletta Bio focused on?
Cabaletta Bio is focused on developing curative targeted cell therapies for patients with autoimmune diseases.
When is Cabaletta Bio's upcoming event?
The upcoming event is a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026.
How can I watch the fireside chat?
The fireside chat can be watched via live webcast on Cabaletta Bio's website in the News and Events section.
What is the lead therapy being developed by Cabaletta Bio?
The lead therapy is rese-cel, a CD19-CAR T cell investigational therapy evaluated in the RESET™ clinical program.
Where are Cabaletta Bio's headquarters located?
Cabaletta Bio's headquarters and labs are located in Philadelphia, PA.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CABA Insider Trading Activity
$CABA insiders have traded $CABA stock on the open market 8 times in the past 6 months. Of those trades, 8 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CABA stock by insiders over the last 6 months:
- STEVEN NICHTBERGER (President & CEO) purchased 45,000 shares for an estimated $100,777
- SHAWN TOMASELLO purchased 22,725 shares for an estimated $50,322
- STEVE GAVEL (Chief Commercial Officer) purchased 22,170 shares for an estimated $50,215
- MARK SIMON purchased 11,061 shares for an estimated $25,261
- GWENDOLYN BINDER (President, Science & Tech.) purchased 11,312 shares for an estimated $24,763
- DAVID J. CHANG (Chief Medical Officer) purchased 8,800 shares for an estimated $19,887
- MICHAEL GERARD (General Counsel) purchased 6,600 shares for an estimated $14,979
- CATHERINE BOLLARD purchased 4,405 shares for an estimated $9,982
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CABA Hedge Fund Activity
We have seen 41 institutional investors add shares of $CABA stock to their portfolio, and 49 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALYESKA INVESTMENT GROUP, L.P. removed 3,500,000 shares (-72.9%) from their portfolio in Q3 2025, for an estimated $8,189,999
- JEFFERIES FINANCIAL GROUP INC. removed 1,949,708 shares (-97.6%) from their portfolio in Q3 2025, for an estimated $4,562,316
- ANSON FUNDS MANAGEMENT LP removed 1,822,830 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $4,265,422
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,568,701 shares (+23.1%) to their portfolio in Q3 2025, for an estimated $3,670,760
- RENAISSANCE TECHNOLOGIES LLC added 1,213,323 shares (+962.2%) to their portfolio in Q3 2025, for an estimated $2,839,175
- BURKEHILL GLOBAL MANAGEMENT, LP removed 1,200,000 shares (-63.2%) from their portfolio in Q3 2025, for an estimated $2,808,000
- MARSHALL WACE, LLP added 1,135,086 shares (+594.4%) to their portfolio in Q3 2025, for an estimated $2,656,101
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CABA Analyst Ratings
Wall Street analysts have issued reports on $CABA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/10/2025
- Cantor Fitzgerald issued a "Overweight" rating on 09/05/2025
To track analyst ratings and price targets for $CABA, check out Quiver Quantitative's $CABA forecast page.
$CABA Price Targets
Multiple analysts have issued price targets for $CABA recently. We have seen 2 analysts offer price targets for $CABA in the last 6 months, with a median target of $23.0.
Here are some recent targets:
- Josh Schimmer from Cantor Fitzgerald set a target price of $30.0 on 10/31/2025
- Douglas Tsao from HC Wainwright & Co. set a target price of $16.0 on 10/10/2025
Full Release
PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 9:30 a.m. ET in New York, NY.
A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com . Replays will be available on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, please visit
www.cabalettabio.com
and connect with us on LinkedIn.
Contacts:
Anup Marda
Chief Financial Officer
[email protected]
